Indinavir in Cerebrospinal Fluid of HIV-1 Infected Patients (Research Letter)

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Indinavir in Cerebrospinal Fluid of HIV-1 Infected Patients (Research Letter)

Lancet (12/20/97-12/27/97) Vol. 35, No. 9094, P. 1823
Stahle, Lars; Martin, Claes; Svensson, Jan-Olof; et al.

Abstract: As part of a population pharmocokinetic project examining protease inhibitors approved in Sweden, researchers from Sweden's Karolinska Institute analyzed the concentration of indinavir in the plasma and cerebrospinal fluid (CSF) of 13 patients by high-pressure liquid chromatography. Samples were taken at various times following drug intake and all patients were stable. Compared with plasma concentration, indinavir in CSF did not vary much over the dose interval. The mean concentration was 0.23 umol/L in CSF and 1.43 umol/L in plasma. These findings, the researchers suggest, show that indinavir reaches the central nervous system in concentrations akin to trough plasma levels. Still, they add, more research is needed to determine the clinical value of indinavir against HIV infection of the central nervous system.

971224
AD972341

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.